the effect of a six week intensified pharmacological treatment for schizophrenia compared to treatment as usual in subjects who had a first-time treatment failure on their first-line treatment.

Conditions: Schizophrenia and Related Disorders; Early Treatment-Resistance

Summary: schizophrenia (sz) affects approximately 4.5 million people across the european union (eu) and is associated with annual healthcare and societal costs of 29 billion euros. the impact on the daily life of patients is huge, ranging from frequent relapses and hospitalisations, the inability to maintain a job or continue scholing, to a low quality of life, impaired cognitive functioning, suicidal ideation and an increase morbidity rate, next to the large burden for carers 1. when diagnosed with schizophrenia or related disorder, patients are commonly prescribed antipsychotics. one-third of the schizophrenia patients are regarded treatment-resistant (tr), meaning that at least two antipsychotic trials have failed. typically, clozapine is prescribed for tr patients, which is effective for approximately 40% of patients. clozapine is among the most effective treatments, with the lowest all-cause mortality. although it is among the most effective antipsychotics, it is generally not used earlier in the illness course due to a small risk of severe neutropenia/agranulocytosis, which is why patients treated with clozapine are intensely monitored. however, this small risk outweighs the burden of not receiving an effective treatment. since clozapine is among the most effective treatments, this leads to the research question whether earlier initiation of third-line treatment ('early intensified' pharmacological treatment; eipt) would be more beneficial than the current second-line treatments (treatment as usual; tau). if this is indeed the case, this could lead to the prevention of unnecessary trials of ineffective treatments, hospitalisations, and recommendations for adaptations of worldwide guidelines as well as a reduction of healthcare and societal costs the intensify-schizophrenia trial is part of the larger horizon 2021 project psych-strata, with the central goal of paving the way for a shift towards a treatment decision-making process tailored for the individual at risk for treatment resistance. to that end, the inestigators aim to establish evidence-based criteria to make decisions of early intense treatment in individuals at risk for treatment resistance across the major psychiatric disorders of schizophrenia, bipolar disorder and major depression. the current protocol focuses on the sample of schizophrenia patients.

rationale schizophrenia (sz) affects approximately 4.5 million people across the european union (eu) and is associated with annual healthcare and societal costs of 29 billion euros. the impact on the daily life of patients is huge, ranging from frequent relapses and hospitalisations, the inability to maintain a job or continue scholing, to a low quality of life, impaired cognitive functioning, suicidal ideation and an increase morbidity rate, next to the large burden for carers. when diagnosed with schizophrenia or related disorder, patients are commonly prescribed antipsychotics. one-third of the schizophrenia patients are regarded treatment-resistant (tr), meaning that at least two antipsychotic trials have failed. typically, clozapine is prescribed for tr patients, which is effective for approximately 40% of patients. clozapine is among the most effective treatments, with the lowest all-cause mortality. although it is among the most effective antipsychotics, it is generally not used earlier in the illness course due to a small risk of severe neutropenia/agranulocytosis, which is why patients treated with clozapine are intensely monitored. however, this small risk outweighs the burden of not receiving an effective treatment. since clozapine is among the most effective treatments, this leads to the research question whether earlier initiation of third-line treatment ('early intensified' pharmacological treatment; eipt) would be more beneficial than the current second-line treatments (treatment as usual; tau). if this is indeed the case, this could lead to the prevention of unnecessary trials of ineffective treatments, hospitalisations, and recommendations for adaptations of worldwide guidelines as well as a reduction of healthcare and societal costs the intensify-schizophrenia trial is part of the larger horizon 2021 project psych-strata, with the central goal of paving the way for a shift towards a treatment decision-making process tailored for the individual at risk for treatment resistance. to that end, the investigators aim to establish evidence-based criteria to make decisions of early intense treatment in individuals at risk for treatment resistance across the major psychiatric disorders of schizophrenia, bipolar disorder and major depression. the current protocol focuses on the sample of schizophrenia patients. objective the primary objective is to compare the treatment response, expressed as mean change in symptom severity as measured through the positive and negative syndrome scale (panss) under an early-intensified pharmacological treatment to that under treatment as usual, in subjects who had a first-time treatment failure on their first-line treatment for schizophrenia, schizoaffective or schizophreniform disorder. main trial endpoints mean change in symptom severity total score from baseline (visit 2) to end of treatment (visit 4) between the two treatment arms (eipt vs. tau). this is measured using panss. secondary trial objectives 1. to compare changes in panss subscale scores (positive, negative and general) between the two treatment arms. 2. to compare changes in severity and improvement in global functioning assessed by the clinical global impression scale (cgi) between the two treatment arms. 3. to compare changes in the levels of depression and anxiety between treatment arms. 4. to compare changes in quality of life and functioning measures between treatment arms. 5. to compare changes in cognitive performance between treatment arms. 6. to compare the proportion of participants (eipt vs. tau) that is in symptomatic remission at visit 4. 7. to compare presence of adverse events (related and unrelated to treatment) between treatment arms. 8. to compare use of concomitant medication between treatment arms. 9. to compare premature treatment discontinuation (timing and reason) between treatment arms. 10. to compare changes in suicidal ideation between treatment arms. trial design the clinical study is an international, multicenter controlled, randomised, open label trial (with blinded raters), with a treatment duration of six weeks. trial population the aim is to recruit 418 subjects with schizophrenia, schizoaffective disorder or schizophreniform disorder. male and female subjects, in- and out-patients, within the age range of 18 to 70 years old are eligible for participation. the main exclusion criteria are defined to protect the wellbeing of subjects, e.g. being pregnant or breastfeeding, subjects with previous failure on clozapine, meeting any contraindications, or participants with a known intolerance to clozapine. interventions subjects are randomised to treatment as usual (second-line treatment) or to the early-intensified pharmacological treatment (third-line treatment; clozapine). ethical considerations relating to the clinical trial including the expected benefit to the individual subject or group of subjects represented by the trial subjects as well as the nature and extent of burden and risks all medications studied in the current trial are widely used (alone or in combination) in clinical practice and side effect profiles are well established. in the current study, clinical practice is mimicked as much as possible to maximize generalizability and for feasibility purposes. to this end, summaries of product characteristics (smpcs) are followed with regards to contraindications (implemented as exclusion criterion), safety measures and prohibited comedications. site visits and assessments are kept to a minimum to keep subject burden at an acceptable level, while meeting the objectives of the study. blood samples for biomarker analyses are only collected when subjects provide consent; safety measures are performed as part of clinical routine. overall, the risks are similar to daily clinical practice; the only difference relative to clinical practice is the application of early-intensified pharmacological treatment earlier in the illness. still, these intense treatment options are also commonly prescribed by clinicians. there are no indications in existing literature or clinical practice that the earlier introduction of these medications poses a safety risk when used in an earlier illness phase than indicated in the smpc. a benefit of the study is that if it indeed turns out that the clozapine is associated with more symptom improvement compared to treatment as usual, future patients have to go through less trial and error, which results in a reduced burden (higher quality of life, less unemployment, less hospitalisations) for patients and carers as well as lower societal and healthcare costs. important: the study was submitted to the european authorities before (see nct05603104) and they requested to split this study into 3 studies (1 for each diagnostic category). we have done this and created 3 new clinicaltrials.gov studies as well, from which this is one for schizophrenia. for the bd study it is nct05973786 and for mdd nct05973851. the site in the uk (london) followed the advice and will submit 3 separate protocols and are therefore included in the current record. however, israel already submitted this as one protocol. therefore, we keep the old clinicaltrials.gov number for israel (nct05603104).

Eligibility criteria:
inclusion criteria: 1. in- or out patients, at least 18 years of age up until 70. 2. being willing and able to provide written informed consent. having a legal guardian to cosign is allowed. informed consent will be signed at visit 1, before any study procedure. 3. female subjects of child bearing potential must use effective contraception during the trial as per the requirements of the applicable smpcs and should have a negative pregnancy test at visit 1 or 2 (before randomisation; section 8.2). 4. meeting diagnostic criteria for a primary diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder, according to dsm-5. the primary diagnosis will be confirmed by the mini international neuropsychiatric interview (mini v7.0.2). 5. subject experiences his/her first treatment failure due to lack of efficacy in the current episode, as confirmed by a cgi-i ≥3; this treatment is a first-line pharmacotherapeutic agent for the primary dsm-5 diagnosis, and was prescribed for at least 4 weeks within an effective dose range as specified in the summary of product characteristics (smpcs). 6. subject and clinician intend to change pharmacotherapeutic treatment. 7. a minimum symptom severity threshold needs to be present (moderate level; see below) and subject needs to experience functional impairment. * the minimum symptom severity threshold is at least 2 panss positive or negative items with a score of 4, or at least one panss positive or negative item with a score of 5. * functional impairment is defined as a score of 5 or higher on any of the three scales of the sheehan disability scale (sds). exclusion criteria: 1. being pregnant or breastfeeding. 2. subject has used clozapine in the past. 3. subject has a known intolerance to clozapine or to all tau medication options. 4. meeting any of the contraindications of clozapine or to all tau medication options, as specified within the applicable smpc. 5. subject has participated in another clinical trial in which the subject received an experimental or investigational drug or agent within 30 days before visit 1. 6. subject experiences any other significant disease or disorder which, in the opinion of the investigator, may either put the subjects at risk because of participation in the trial, or may influence the result of the trial, or the subject's ability to participate in the trial. 7. subjects with active suicidal ideation with some intent to act, without specific plan ("yes" to question 4 of the columbia-suicide severity rating scale (c-ssrs)) or active suicidal ideation with specific plan and intent ("yes" to question 5 of the c-ssrs), followed by an assessment by the treating clinician who determines it is not safe for the subject to participate in the study 8. subject meets criteria for current substance use disorder, as confirmed by the mini international neuropsychiatric interview (mini v7.0.2). nicotine dependency is allowed, as well as mild and moderate alcohol and/or cannabis use disorder (as defined by mini v7.0.2). severe alcohol and/or cannabis use disorder are not allowed. 9. subjects have not been committed to an institution by virtue of an order issued either by the judicial or the administrative authorities. 10. subjects who meet the modified andreasen criteria for remission. 11. subjects that have any clinically significant abnormal values on the local laboratory test (especially anc/wbc and liver values), electrocardiogram (ecg) or physician examinations. 12. subjects dependent on the sponsor, investigator or trial site must be excluded from participation in advance

Keywords: schizophrenia schizoaffective disorder schizophreniform disorder clozapine treatment as usual early treatment-resistance